Dapagliflozin And Vildagliptin 10/100 DAPA VILDA 10/100 SR is a cutting-edge medication designed for the treatment of type 2 diabetes, offering a robust combination of two active pharmaceutical ingredients to effectively manage blood glucose levels. This medication features 10 mg of Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and 100 mg of Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in a sustained-release (SR) formulation. Dapagliflozin functions by blocking the reabsorption of glucose in the kidneys, promoting its excretion through urine, thereby reducing blood glucose levels. On the other hand, Vildagliptin enhances the function of incretin hormones, which increases insulin release and decreases glucagon production in response to meals. The combination of these two mechanisms in DAPA VILDA 10/100 SR not only aids in maintaining stable blood sugar levels throughout the day but also supports overall metabolic health. This medication is particularly beneficial for individuals with type 2 diabetes who need a comprehensive approach to control their blood sugar, offering an extended-release profile to ensure consistent therapeutic effects. For further information please contact: info@sterispharma.com / contact@sterispharma.com call/whatsapp: 8209542042, 8955945010, 6377716668 order now: https://www.sterisonline.com/product/dapa-vilda-10-100-sr-134064